-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-819 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-819 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Diffuse Large B-Cell Lymphoma Drug Details: KITE-222...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nacubactam in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nacubactam in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nacubactam in Urinary Tract Infections Drug Details: Nacubactam (RG6080, RO7079901) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olutasidenib in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olutasidenib in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olutasidenib in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olutasidenib in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olutasidenib in Myelodysplastic Syndrome Drug Details: Olutasidenib (Rezlidhia) is an isocitrate dehydrogenase-1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-819 in B-Cell Acute Lymphocytic...
-
Analyst Opinions
Digging Deeper into Sustainability – Key Disruptive Forces in Mining (Vol.3)
Disruptive Forces in Mining Report Overview The demand for cleaner and more sustainable energy solutions such as flow batteries is rising owing to growing ESG pressure. Flow batteries have emerged as a promising technology that can contribute to a more reliable and environmentally friendly energy landscape. Leading players as well as startups are investing in developing sustainable solutions. For instance, the new kind of sodium batteries, being developed by startups such as Finland-based Broadbit and India-based AR4 Tech offer much...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: XmAb-717 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-172154 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-172154 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SL-172154 in Myelodysplastic Syndrome Drug Details: SL-172154 is under development for the...